Bessemer Group Inc. Sells 3,655 Shares of Moderna, Inc. $MRNA

Bessemer Group Inc. lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 31.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,949 shares of the company’s stock after selling 3,655 shares during the quarter. Bessemer Group Inc.’s holdings in Moderna were worth $219,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of MRNA. OneDigital Investment Advisors LLC boosted its position in shares of Moderna by 9.9% in the first quarter. OneDigital Investment Advisors LLC now owns 8,696 shares of the company’s stock valued at $247,000 after acquiring an additional 785 shares during the period. IFM Investors Pty Ltd boosted its position in shares of Moderna by 5.3% in the first quarter. IFM Investors Pty Ltd now owns 64,100 shares of the company’s stock valued at $1,817,000 after acquiring an additional 3,227 shares during the period. World Investment Advisors boosted its position in shares of Moderna by 30.5% in the first quarter. World Investment Advisors now owns 9,262 shares of the company’s stock valued at $263,000 after acquiring an additional 2,163 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Moderna by 1.8% in the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company’s stock valued at $54,382,000 after acquiring an additional 34,034 shares during the period. Finally, Brown Advisory Inc. boosted its position in shares of Moderna by 92.2% in the first quarter. Brown Advisory Inc. now owns 14,080 shares of the company’s stock valued at $399,000 after acquiring an additional 6,755 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Citigroup cut their price objective on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. Morgan Stanley upped their price objective on shares of Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. Barclays cut their price objective on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a research report on Monday, August 4th. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $36.86.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $24.91 on Tuesday. The company has a 50 day simple moving average of $25.85 and a 200 day simple moving average of $27.18. The firm has a market cap of $9.73 billion, a PE ratio of -3.31 and a beta of 2.02. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $56.69.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. The business had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company’s revenue for the quarter was down 41.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($3.33) EPS. As a group, research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.